New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2014
14:48 EDTMDCO, SNSS, EWP, TC, MURHigh option volume stocks: TC SNSS MUR EWP MDCO
News For TC;SNSS;MUR;EWP;MDCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 13, 2015
06:39 EDTTCThompson Creek reports Q3 production for Mount Milligan 31,700 dry tonnes
Thompson Creek Metals Company announced production and sales results for the Q3. Total concentrate production for Mount Milligan for the Q3 was 31,700 dry tonnes, with 16.3M pounds of payable copper and 53.8 thousand ounces of payable gold, which represents an increase of approximately 1% and a decrease of 11%, respectively, from payable copper and gold production during the Q3 of FY14. For the Q3, daily mill throughput averaged 44,077 tonnes and mill availability averaged 90.2%. Recoveries averaged 76.1% for copper and 67.3% for gold. A significant amount of oxidized material was processed during the Q3 which, as expected, adversely impacted recoveries.
06:33 EDTTCThompson Creek reports Q3 production 31,700 dry tonnes
Subscribe for More Information
October 9, 2015
08:30 EDTMDCOBioNJ to hold a summit
Subscribe for More Information
October 7, 2015
16:04 EDTSNSSSunesis Chief Medical Officer Adam Craig to step down at end of year
Subscribe for More Information
16:03 EDTSNSSSunesis to submit MAA for vosaroxin with EMA by end of 2015
Sunesis Pharmaceuticals announced that the company intends to submit a Marketing Authorization Application for vosaroxin as a treatment for acute myeloid leukemia with the European Medicines Agency by the end of 2015. The company recently announced that it met separately with the Rapporteur (United Kingdom) and Co-Rapporteur (Netherlands) assigned to provide advice and guidance to the company through the MAA process. Based on these discussions, the company is proceeding with an MAA filing for the indication of relapsed/refractory AML in patients age 60 years and older, a population with the greatest medical need and for whom the greatest benefit was observed in the vosaroxin/cytarabine treatment arm of VALOR, the company's pivotal Phase 3 study of vosaroxin and cytarabine in adult patients with relapsed or refractory AML.
October 6, 2015
17:16 EDTMDCOThe Medicines Co., SymBio Pharmaceuticals enter strategic partnership in Japan
Subscribe for More Information
15:37 EDTMURMurphy Oil files automatic mixed securities shelf
October 5, 2015
07:31 EDTMDCOThe Medicines Co. ALN-PCSsc 'a potential game changer,' says RBC Capital
After examining surveys and speaking with experts, RBC Capital says that the uptake of The Medicines Co's ALN-PCSsc treatment has been strong among anti-PCSK9 patients, reaching 20%-30%. The firm estimates that the company could conservatively generate $9B-$18B in revenue from the drug. It believes that the product is "a potential game changer and valuation driver" for the company. RBC keeps a $46 price target and Outperform rating on the shares.
October 1, 2015
07:05 EDTMDCOMedicines Company says BARDA exercises option on Carbavance pact
The Medicines Company announced that Rempex Pharmaceuticals, a wholly owned subsidiary, has been awarded the next option on a contract by the Biomedical Advanced Research and Development Authority, or BARDA, to support the development of CARBAVANCE. CARBAVANCE is the combination of a carbapenem antibiotic with a novel beta-lactamase inhibitor that is targeted for treatment of multi-drug resistant gram-negative infections, including those due to carbapenem-resistant Enterobacteriaceae. The cost-share contract with BARDA was initiated in 2014 and extends over 5 years. The award of this third option brings the total commitment from BARDA to $53.8M. If all options are exercised in the contract, it would bring the total value of the award to approximately $90M.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use